title: [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy].
abstract: Prostate cancer is one of the main health problems of the male population. Radical prostatectomy has demonstrated to have an excellent long-term cure rate. Nevertheless, globally, a 25% of the operated patients will suffer a PSA increase over 15 years of follow-up. Generally, the PSA value associated with a higher risk of clinical progression, that may be established as the cut point for biochemical recurrence is 0.4 ng/ ml. Once biochemical recurrence is diagnosed, the most important clinical data is to determine if clinical recurrence is going to be local or systemic, because it will determine treatment. Main parameters helping to differentiate between one and another are: time interval to PSA increase, PSA velocity, PSA doubling time (PSA-DT), pathologic stage and specimen's Gleason's score. The possibilities of treatment of biochemical failure after radical prostatectomy are under debate. Nevertheless, it is currently considered that patients with biochemical recurrence without radiological evidence of distant metastases are ideal candidates for local treatment with radiotherapy.
authors.affiliation: Servicio de Urología, Instituto Valenciano de Oncología (IVO), Valencia, España. argimirocollado@usa.net
authors.forename: Argimiro Collado
authors.initials: AC
authors.lastname: Serra
authors.forename: Eduardo Solsona
authors.initials: ES
authors.lastname: Narbón
mesh_terms: D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis*; D016609:Neoplasms, Second Primary / Q000097:blood* / Q000175:diagnosis*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000601:surgery*
chemical_list: D017430:Prostate-Specific Antigen